CKD Drug Map 2026: Approval Wave & Next-Gen Race
CKD drug market analysis for 2025-2026. Covers IgA nephropathy approvals, aldosterone synthase inhibitor Phase 3 race, key M&A, and corporate positioning.
Introduction
The CKD (Chronic Kidney Disease) therapeutics market is undergoing a historic transformation in the mid-2020s. Following the "first wave" of SGLT2 inhibitors and Finerenone establishing themselves as standard of care, 2025-2026 has seen a simultaneous convergence of IgA nephropathy approval waves, Phase 3 competition among aldosterone synthase inhibitors (ASIs), and endothelin receptor antagonist (ERA) label expansions.
This article analyzes the CKD landscape from a business perspective—who is winning, who is struggling, and where the market is heading. For detailed clinical data and mechanisms of action, see our comprehensive CKD drug clinical and mechanism guide.
1. Market Overview: Structural Shifts in CKD Therapeutics
1.1 Market Size & Growth Drivers
The global CKD therapeutics market is estimated at approximately $15 billion in 2025, with projections exceeding $30 billion by 2030. Three structural factors drive this explosive growth:
- Expanding patient population: ~800 million people worldwide (about 10% of adults) have CKD, with prevalence rising alongside aging populations and the diabetes/obesity epidemic.
- Treatment paradigm shift: A transition from symptomatic blood pressure management to disease-modifying therapies (DMTs) that directly target fibrosis and inflammation.
- Advances in diagnostics: Wider adoption of UACR and eGFR screening is identifying treatable patients earlier, expanding the addressable market.
1.2 Competitive Landscape at a Glance
| Segment | Key Players | 2025-2026 Status |
|---|---|---|
| Established SoC | Bayer (Finerenone), AstraZeneca (Dapagliflozin), Novo Nordisk (Semaglutide) | Embedded in KDIGO guidelines; market foundation established |
| IgA Nephropathy | Novartis (Atrasentan, Iptacopan), Otsuka (Sibeprenlimab), Travere (Sparsentan) | Approval wave: 4 drugs approved/filed in 2024-2025 |
| Next-Gen ASI | AstraZeneca (Baxdrostat), BI (Vicadrostat), Mineralys (Lorundrostat) | Phase 2→3 transition: Three-way race |
| ERA | AstraZeneca (Zibotentan), Novartis (Atrasentan) | Exploring label expansion into diabetic kidney disease |
| FSGS | Travere (Sparsentan), BI (Apecotrep), Vertex (Inaxaplin) | April 13, 2026: Sparsentan (Filspari) FDA first-ever approval for FSGS, Apecotrep Phase 3 recruiting |
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Key Events 2025-2026: Approvals, Successes, & Setbacks
2.1 Approvals & Phase 3 Successes (Green Light)
Sparsentan (Travere Therapeutics) — Dual Approval: IgAN (2024) + FSGS (April 13, 2026)
- Dual ET/AT1 antagonist: IgA nephropathy full approval (2024) followed by FSGS FDA full approval on April 13, 2026
- First-ever approved drug for FSGS (see Sparsentan FSGS Approval — Full Breakdown)
- Efficacy established across two distinct glomerular diseases (PROTECT for IgAN, DUPLEX for FSGS)
- Travere's flagship commercial asset now spans two major glomerular disease indications
Atrasentan (Novartis) — FDA Accelerated Approval 2025
- ALIGN trial demonstrated efficacy in IgA nephropathy
- Novartis acquired Chinook Therapeutics in June 2023 for ~$3.2B upfront to obtain this asset
- Part of a "dual-asset strategy" alongside Iptacopan (complement Factor B inhibitor)
Sibeprenlimab / Voyxact (Otsuka / Visterra) — FDA Accelerated Approval, Nov 2025
- APRIL-inhibiting antibody; FDA accelerated approval (Nov 25, 2025) for proteinuria reduction in IgA nephropathy
- Confirmatory trial (VISIONARY) ongoing to verify long-term renal protection
- Monthly subcutaneous injection offers convenience differentiation
- A new pillar for Otsuka's nephrology franchise
Iptacopan / Fabhalta (Novartis) — C3 Glomerulopathy Approval 2025
- Complement Factor B inhibitor: 38% proteinuria reduction in APPLAUSE-IgAN
- Oral formulation differentiates against injectable competitors
- Sequential approvals in IgA nephropathy and C3G strengthen Novartis's portfolio
Finerenone Label Expansion — FINE-ONE Trial Success
- Demonstrated UACR reduction in T1D-associated CKD
- T1D label expansion anticipated in 2026
- Further solidifies Bayer's renal franchise
2.2 Phase 3 in Progress (Key Watchlist)
Vicadrostat / BI 690517 (Boehringer Ingelheim)
- ASI frontrunner by trial scale
- Phase 3 EASi-KIDNEY: ~11,000 patients across 15-20 countries
- Empagliflozin combination strategy to compete with AZ's Baxdrostat
Baxdrostat (AstraZeneca)
- Dapagliflozin combination Phase 3 in progress
- AZ acquired CinCor Pharma for ~$1.8B in 2023 to obtain this asset
- "In-house complete package" (SGLT2i + ASI) is a strategic advantage
Zibotentan + Dapagliflozin (AstraZeneca)
- ERA + SGLT2i combination to offset fluid retention risk
- ZENITH High Proteinuria Phase 3 ongoing
- If successful, AZ builds a CKD "triple stack" (SGLT2i + ASI + ERA)
2.3 Notable M&A Activity
CKD has seen a wave of multi-billion-dollar acquisitions in 2023-2025, signaling big pharma's conviction that this is the next major market opportunity.
| Year | Acquirer | Target | Deal Value | Key Asset |
|---|---|---|---|---|
| Jun 2023 | Novartis | Chinook Therapeutics | ~$3.2B | Atrasentan (ERA) |
| 2023 | AstraZeneca | CinCor Pharma | ~$1.8B | Baxdrostat (ASI) |
| 2023 | Otsuka | Visterra (full integration) | Undisclosed | Sibeprenlimab (APRIL) |
These acquisitions underscore the consensus view that CKD/renal fibrosis represents the next blockbuster therapeutic area.
3. Competitive Landscape Visualization
Legend:
- Green: Approved
- Blue: Phase 3 in progress
- Yellow: Phase 2 (transitioning)
4. Strategic Analysis: Corporate Positioning
Novartis — IgA Nephropathy "Dual-Asset" Play
Novartis holds two mechanistically distinct drugs—Atrasentan (ERA) and Iptacopan (complement Factor B inhibitor)—both approved for IgA nephropathy. The $3.2B Chinook acquisition is paying dividends, and the company is well-positioned to dominate the IgA market through combination strategies and head-to-head differentiation.
AstraZeneca — CKD "Full-Stack" Strategy
AstraZeneca is building a vertically integrated CKD portfolio: Dapagliflozin (SGLT2i) as the foundation, with Baxdrostat (ASI) and Zibotentan (ERA) layered on top. Owning all three assets in-house enables seamless combination trial design and unified commercial messaging.
Bayer — Finerenone "Label Expansion" Play
Bayer is methodically expanding Finerenone's addressable market from T2D-CKD to T1D-CKD. The CONFIDENCE trial data (52% UACR reduction with Finerenone + SGLT2i) provides powerful ammunition for combination therapy positioning.
Boehringer Ingelheim — "IPF + CKD" Cross-Disease Approach
Following Nerandomilast approval in IPF, Boehringer is advancing Vicadrostat (ASI) in CKD. This "pan-fibrosis" approach positions the company uniquely across multiple fibrotic diseases, potentially enabling cross-indication learnings and shared commercial infrastructure.
5. What to Watch: 2026H2 and Beyond
- ASI race resolution: Vicadrostat (BI) and Baxdrostat (AZ) Phase 3 readouts will determine first-mover advantage in this high-stakes segment.
- Guideline updates: KDIGO 2026-2027 revisions may formally recommend quadruple therapy (RAS + SGLT2i + Finerenone + GLP-1RA), reshaping prescribing patterns.
- IgA nephropathy market maturation: With 4 approved drugs, differentiation by route of administration (oral vs. injectable), mechanism, and long-term data becomes critical.
- Biosimilar impact: Dapagliflozin patent expiry timelines (varying by geography from 2026 onward) could reshape the SGLT2i market.
- FSGS competition intensifies: Following Sparsentan's April 2026 approval, Apecotrep (BI, TRPC6 inhibitor, Phase 3 recruiting) and Inaxaplin (Vertex, APOL1-targeted, AMPLITUDE Phase 3) will deliver pivotal data in 2026-2027. Whether any competitor can surpass the newly established Filspari benchmark is the defining question in FSGS drug development.
6. Conclusion
The CKD therapeutics market has decisively transitioned from a "one-to-two drug era" to a "layered combination era" in 2025-2026. Novartis's IgA dual-asset play, AstraZeneca's full-stack strategy, and Boehringer's pan-fibrosis approach represent clearly differentiated corporate visions competing for market leadership.
For companies developing new CKD therapeutics, demonstrating add-on efficacy over this already-powerful standard of care is the critical success factor in clinical trial design. At the preclinical stage, selecting the appropriate renal fibrosis model aligned with a candidate's differentiation strategy—whether anti-fibrotic, anti-inflammatory, or metabolic—remains the key to translational success.
References & Clinical Trial Information
Established Standard of Care
1. Bakris GL, et al. Effect of Finerenone on CKD Outcomes in T2D. N Engl J Med. 2020;383:2219-2229. (FIDELIO-DKD: NCT02540993)
2. Heerspink HJL, et al. Dapagliflozin in CKD. N Engl J Med. 2020;383:1436-1446. (DAPA-CKD: NCT03036150)
3. Perkovic V, et al. Semaglutide in CKD. N Engl J Med. 2024. (FLOW: NCT03819153)
IgA Nephropathy & Complement
4. Atrasentan ALIGN Phase 3: NCT04573478
5. Iptacopan APPLAUSE-IgAN Phase 3: NCT04578834
6. Sibeprenlimab VISIONARY Phase 3: NCT05248646
ASI (Aldosterone Synthase Inhibitors)
7. Vicadrostat EASi-KIDNEY Phase 3: NCT06531824
8. Baxdrostat + Dapagliflozin Phase 3: NCT06268873
ERA (Endothelin Receptor Antagonists)
9. Zibotentan + Dapagliflozin ZENITH Phase 3: NCT06087835
Combination Therapy
10. Green JB, et al. Finerenone and Empagliflozin in DKD. N Engl J Med. 2025. (CONFIDENCE: NCT05254002)
Related Articles
Individual Drug Deep-Dives
- Finerenone (Kerendia): nsMRA for DKD/HFpEF
- Iptacopan (Fabhalta): Factor B Inhibitor for IgAN/PNH/C3G
- Sibeprenlimab (Voyxact): anti-APRIL FDA Accelerated for IgAN
- Atrasentan (Vanrafia): ETA-Selective Antagonist for IgAN
- Inaxaplin (VX-147): APOL1 Channel Inhibitor for AMKD
- Atacicept: BAFF+APRIL Dual Inhibitor for IgAN Phase 3
- Sparsentan (Filspari) FSGS Approval 2026 — First-Ever FDA Drug for FSGS